Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam…
<!-- Name:DistributionId Value:8744881 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Cassava Sciences
No Evidence of Data Manipulation in Science Publication on Simufilam
AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the…
Cassava Sciences Responds to Media Reports
- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior…
FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients
AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the…
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral…
New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants.Rethink-ALZ.com connects patients with nearest participating clinical…
Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005…
Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This…
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously…
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma…
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program…
AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the selection of Premier…
Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress…
Open-label Study Completes Patient EnrollmentCognition Maintenance Study Initiated May 2020, now 30% Enrolled6-month Biomarker Data to be Presented at AAIC Conference in July9-month Safety…